Relay Therapeutics (RLAY) TD Cowen 46th Annual Health Care Conference summary

Strategic focus and portfolio updates

• Capital allocation prioritized to advance zovegalisib, extending cash runway into 2029 and focusing on three major clinical areas: breast cancer (2nd and 1st line) and PI3Kα-driven vascular anomalies.

• Outlicensed the most advanced clinical program to concentrate resources on core assets.

• Three key datasets planned for disclosure in the coming year to de-risk major opportunities for stakeholders.

Clinical development highlights

• Upcoming data from 57 patients on 400 mg BID fed zovegalisib in 2nd-line metastatic breast cancer to be presented at ESMO TAT, aiming for consistency with prior results and to de-risk phase III trial.

• Phase III ReDiscover-2 trial is enrolling globally, with progress on track but no specific guidance on full enrollment yet.

• Frontline breast cancer trial design and go-forward regimen to be disclosed this year, focusing on tolerability in triplet combinations.

Vascular anomalies program

• Phase II ReInspire study of zovegalisib in vascular malformations started in Q1 last year, targeting both adults and children.

• Initial data will focus on PROS patients, with expansion to lymphatic and venous malformations over time.

• Estimated 100,000 relevant patients in the US, with about 25,000 likely to seek chronic systemic therapy.

• Study design includes randomized dose optimization in patients 12+ years, with expansion cohorts and potential for accelerated approval based on ORR by volumetric MRI.

• Safety and tolerability are critical due to chronic use in a largely pediatric population.